VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | AML haplo-HSCT outcomes

Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the results of a study evaluating the outcomes of acute myeloid leukemia (AML) patients receiving a haploidentical hematopoietic stem cell transplant (haplo-HSCT) with thiotepa/busulfan/fludarabine (TBF) conditioning and post-transplant cyclophosphamide versus a matched unrelated donor with fludarabine/busulfan conditioning. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter